The mission of the University of Arizona Cancer Center Analytical Chemistry Shared Resource (ACSR) is to provide Cancer Center investigators with centralized resources and expertise in performing analytical chemistry assays and pharmacokinetic (PK) and pharmacodynamic (PD) data analysis and interpretation.
The Analytical Chemistry Shared Resource has accumulated considerable experience in quantitative analysis of small molecules (<1,500 daltons) in biological specimens. ACSR is capable of providing integrated PK service from the study design stage through quantification of drug levels to PK/PD data analysis. In addition, ACSR has developed the capabilities to support targeted metabolomics analysis and untargeted metabolomics profiling.
Specifically, the ACSR has the following aims:
- To develop and implement chromatography-mass spectrometry-based analytical chemistry methods for quantification of cancer therapeutic and preventive agents, nutrients, carcinogens, endogenous biochemicals, and imaging agents;
- To perform quantitative and qualitative analysis of cancer therapeutic and preventive agents, nutrients, carcinogens, endogenous biochemicals, and imaging agents;
- To provide consultation in pharmacokinetic study design and pharmacokinetic and pharmacodynamic data analysis.
ACSR has continued to build its repository of analytical assay protocols, many of which can be readily applied to new projects, and thus the ACSR is able to support a broad spectrum of research projects in a cost-effective manner and with a rapid turnaround time. By continuing to provide state-of-the-art analytical chemistry and pharmacokinetic services, the ACSR laboratory greatly augments pre-clinical drug discovery efforts, stimulates the incorporation of pharmacokinetic endpoints in clinical trials, and facilitates biomarker analysis in cancer prevention and control research.
To build a project, get a quote, or order a service within iLab:
- Step 1: Select “About Our Core” to learn more about this Shared Resource.
- Step 2: Login or sign up for an iLab account here, at the University of Arizona. For login help, email iLab-support@agilent.com.
- Step 3: Once the login step is completed, obtaining prices, services and scheduling is available within the iLab system.
Please remember to acknowledge the Cancer Center Support Grant (P30 CA023074) when publishing manuscripts or abstracts that utilized the services of the University of Arizona Cancer Center’s Shared Resources and/or were derived from CCSG pilot funds. Suggested language: "Research reported in this [publication/press release] was supported by the National Cancer Institute of the National Institutes of Health under award number P30 CA023074.
Analytical Chemistry Shared Resource
- Consultation on study design including selection of established, validated assays from the analytical assay protocol repository and/or development of new assays
- Development/implementation of analytical chemistry assays for quantification of small molecules (<1,500 daltons) in biological specimens
- Quantitative analysis of small molecules in clinical and preclinical samples using chromatography and mass spectrometry-based systems or atomic absorption spectrophotometry
- Performance of targeted metabolomics analysis and untargeted metabolomics profiling
- Pharmacokinetic study design, quantitative analysis of drug levels, and pharmacokinetic and pharmacodynamics data analysis
Services provided by the ACSR are essential for the assessment of drug/nutrient/carcinogen exposure and disposition, and for the measurement of endogenous biochemicals as surrogate cancer-risk biomarkers and endpoint biomarkers in intervention studies. These measurements are indispensable in many established lines of research in the University of Arizona Cancer Center, including preclinical and clinical evaluation of cancer therapeutic drugs and preventive interventions, assessment of biological, environmental, and lifestyle factors associated with cancer risk and disease progression, and identification of potential targets for intervention. The services provided by the ACSR are playing an increasingly important role in the emerging field of metabolomics that is reshaping the research directions of cancer research in general.
State-of-the-art equipment and sophisticated analytical chemistry techniques are provided by the ACSR to cover a broad variety of needs. Personnel are trained experts in the operation and maintenance of the equipment. They have the expertise to develop and optimize the appropriate methods. Major equipment includes:
- Agilent Ultivo Triple Quadrupole Mass Spectrometer with 1290 Ultra Performance Liquid Chromatography System
- Agilent 6495 Triple Quadrupole Mass Spectrometer with 1290 Ultra Performance Liquid Chromatography System
- ThermoFinnigan TSQ Quantum Ultra Mass Spectrometer with High Performance Liquid Chromatography System
- Waters Xevo G2-S QToF Mass Spectrometer with Ultra Performance Liquid Chromatography System
- ThermoFinnigan Trace DSQ Gas Chromatography Mass Spectrometer System
- Perkin Elmer Aanalyst 600 Atomic Absorption Spectrophotometer System
- Thermo TSQ Quantum Ultra Mass Spectrometer (3rd Generation) High Performance Liquid Chromatography
- Sciex 5500 QTrap Mass Spectrometer with Ultra High Performance Liquid Chromatography
- Agilent Intuvo 9000 Gas Chromatography with Flame Ionization Detector
- Access to Thermo Exploris 480 with Thermo Vanquish Horizon Duo Ultra High Performance Liquid Chromatograph
Metabolomics and Lipidomics
The Analytical Chemistry Shared Resource (ACSR) has developed a metabolomics and lipidomics program to profile these small molecules in biofluids, cells and tissues. These analyses are routinely used for biomarker discovery and to identify regulation of molecular pathways. Lipid and polar metabolite libraries provide confident identification of over 500 compounds from plasma, urine, tissues, and cell lines. These libraries complement the burgeoning untargeted metabolomics/lipidomics program in ACSR that revolves around a state-of-the-art Thermo Vanquish Duo UPLC tandem Exploris 480 Q-Orbi Mass Spectrometer (LC/MS/MS).
Metabolites are acquired with both HILIC and Reverse Phase chromatography in positive ion mode to provide comprehensive metabolome coverage. Specialty Reverse Phase chromatography and libraries have been developed for lipidomics analysis. Metabolomics data can be further enhanced through a statistical pipeline (being developed by BBSR) and metaboanalyst analysis that provide pathway enrichment and network analysis to pinpoint nodes of regulation. Lipidomics analysis is enhanced through custom R code to analyze lipid class, degrees of saturation, and chain length.
<<If you cannot see all 3 columns on your mobile device, please rotate your device to a landscape position>>
Analyte |
Sample Type |
Instrument |
---|---|---|
2-AG(2-Arachidonoylglycerol), AEA(N-arachidonoylethanolamine) |
Brain, brain perfusate |
HPLC-MS/MS |
4-HPR (N-(4-hydroxyphenyl)-retinamide) |
Plasma; Tissue |
HPLC-FLD |
5-FU (Fluorouracil) |
Cells |
HPLC-MS/MS |
8-Hydroxy-2'-deoxyguanosine |
Urine; DNA |
HPLC-MS/MS |
8-Isoprostaglandin F2 alpha |
Urine; Plasma |
HPLC-MS/MS |
Acetylcholine |
Mouse cortex |
HPLC-MS/MS |
AH1S2(iron chelator) |
Mouse Plasma |
HPLC-MS/MS |
Alpha-tocopheryloxyacetic acid |
Plasma |
HPLC-MS/MS |
Amino Acids |
Cell Culture |
HPLC-MS/MS |
AMP423(naphthyl derivative of 2-cyanoaziridine-1-carboxamide) |
Formulation Preparation |
HPLC-MS |
Aspirin |
Plasma |
HPLC-MS/MS |
Antalarmin |
Plasma |
HPLC-MS/MS |
Arginine/Ornithine |
Intestine; |
HPLC-FLD |
AZ002S |
Mouse Plasma |
HPLC-MS/MS |
AZD/Ponatinib |
Plasma |
HPLC-MS/MS |
Bile acids |
Fecal Water; Plasma; |
HPLC-MS |
Bile acids (parent bile acids and taurine and glycine conjugates) |
Gastric fluid |
HPLC-MS/MS |
Bixin |
Plasma |
HPLC-UV |
Buspirone |
Plasma |
HPLC-MS/MS |
C391 |
Plasma |
HPLC-UV-MS |
Caffeine/Caffeine metabolites |
Plasma |
HPLC-UV; |
Carbendazim |
Plasma |
HPLC-MS/MS |
Carotenoids |
Plasma; Skin |
HPLC-FLD |
Celecoxib |
Plasma |
HPLC-UV |
Ceramide |
Cells; plasma; |
*HPLC-MS/MS |
Ceramide-1-Phosphate |
Cells; plasma; |
*HPLC-MS/MS |
cGMP |
Cell Extract |
HPLC-MS/MS |
Chlorophyll |
Colon Tissue |
HPLC-FLD |
Compound L |
Mouse Plasma |
HPLC-MS/MS |
Cortisol/6-Hydroxycortisol |
Urine |
HPLC-UV |
Cortisol/Cortisone |
Saliva |
HPLC-MS/MS |
Curcumin |
Plasma; Urine; Skin |
HPLC-UV; |
Cytarabine + nucleosides |
Cells |
HPLC-MS/MS |
Dexmedetomidine |
Urine |
HPLC-MS/MS |
Dextromethorphan (DM)/DM metabolites |
Urine |
HPLC-FLD |
DFMO (Alpha-difluoromethylornithine) |
Plasma; Skin |
HPLC-FLD |
Diacylglycerides |
Cells; plasma; |
*HPLC-MS/MS |
Dihydrotestosterone |
Cytosolic extract |
HPLC-MS |
DIM (diindolylmethane) |
Urine |
HPLC-MS/MS |
Diphenidol |
Cell culture media |
HPLC-MS/MS |
DITPA (3,5-diiodothyropropionic acid) |
Plasma |
HPLC-MS/MS |
Dopamine |
Mouse Cortex |
HPLC-MS/MS |
Doxorubicin |
Tissue (mouse tumor) |
UPLC-TOF-MSe |
DPC0046 |
Plasma |
HPLC-MS/MS |
Endocannabinoids |
Plasma |
*HPLC-MS/MS |
Epinephrine |
Mouse cortex |
HPLC-MS/MS |
Estrone/Estradiol +13 metabolites |
Plasma; urine |
HPLC-MS/MS |
Fatty acids |
Plasma |
HPLC-MS/MS |
FICZ(6-Formylindolo(3,2-b)carbazole) |
PBS |
HPLC-MS |
GABA (gamma-aminobutyric acid) |
Mouse Cortex; Urine |
HPLC-MS/MS |
gamma-Glutamylcysteine |
Cell extract |
HPLC-FLD |
Gemcitabine Triphosphate |
Blood Lymphocytes; |
HPLC-UV |
Gemcitabine |
Plasma; Tissue; Cell Extract |
HPLC-UV; |
Genistein |
Plasma |
HPLC-MS/MS |
Glutamate |
Mouse Cortex |
HPLC-MS/MS |
Glyoxal, Methyl glyoxal |
Cell extract |
GC-MS |
5-,8-,11-,12-,15-,20-HETEs (hydroperoxyeicosatetraenoic acid) |
Lung Tissue |
HPLC-MS/MS |
Hexosylceramide/LactosylCer |
Cells; plasma; Urine; tissue |
*HPLC-MS/MS |
HPMA(N-(2-Hydroxypropyl)methacrylamide), SPMA |
Urine |
HPLC-MS/MS |
Imexon |
Plasma |
HPLC-UV |
Iron |
Cell Extract |
AAS |
Isothiocyanate-glutathione conjugates |
Cultured cells |
HPLC-MS/MS |
Kynurenine Pathway Metabolites*** |
Urine, plasma, liver |
HPLC-MS/MS |
LTE4(Leukotriene E4) |
Urine |
HPLC-MS/MS |
Limonene |
Plasma; breast tissue, |
HPLC-MS/MS; |
Losartan/Losartan Metabolites |
Urine; Plasma |
HPLC-UV; |
Malondialdehyde |
Cell extract |
GC-MS |
Melphalan/Melphalan analogues |
Dosing Preparation |
HPLC-MS/MS |
Metformin |
Plasma; Cell culture media; |
HPLC-MS/MS |
Methyl-4-aminosalicylate |
Pure Standard |
HPLC-UV |
Metronidazole |
Cells |
HPLC-MS/MS |
Midazolam/ Midazolam Metabolites |
Plasma |
HPLC-MS/MS |
Napthazarin |
Pure Standard |
HPLC-UV-MS/MS |
Nitotinic acid/Nicotinamide |
Plasma |
HPLC-MS/MS |
Nitrite |
Cell culture media |
HPLC-FLD |
Norepinephrine |
Mouse cortex |
HPLC-MS/MS |
NPA-093 |
Plasma |
HPLC-UV |
Nucleoside Triphosphates/deoxyNucleoside Triphosphates |
Cell extract |
HPLC-MS/MS |
Omeprazole/Metabolites |
Plasma |
HPLC-MS/MS |
Oxylipins(69 individual**) |
Plasma |
UPLC-TOF-MS |
Pazopanib |
Plasma |
HPLC-MS/MS |
Pemetrexed (Alimta®) |
Plasma; IP fluid |
HPLC-MS/MS |
Pentosidine |
Plasma |
HPLC-FLD |
PGE-M |
Urine |
HPLC-MS/MS |
Phenethylamine |
Urine |
HPLC-MS/MS |
Phthalates (mono- and di-butyl phthalate) |
Plasma; Tissue |
HPLC-MS/MS |
PHT-427 (Akt/phosphatidylinositide-dependent |
Plasma; Tissue |
HPLC-UV; |
PhytoCeramide |
Yeast |
*HPLC-MS/MS |
PMIP (therapeutic peptide) |
Plasma |
HPLC-MS/MS |
Polyamines |
Plasma; Tissue |
HPLC-FLD |
Psorospermin methyl ether |
Plasma |
HPLC-UV |
PX-12(1-methylpropyl 2-imidazolyl disulfide) |
Plasma |
HPLC-UV; |
Quercetin |
Plasma; skin |
HPLC-MS/MS |
Radicicol |
Plasma |
HPLC-MS/MS |
Rapamycin |
Whole blood |
HPLC-MS/MS |
Resveratrol |
Plasma; Tissue |
HPLC-MS/MS |
Retinols(Retinol, all-trans retinoic acid, 9-cis retinoic acid) |
Plasma; Skin, Mouse Tissue |
HPLC-FLD/HPLC-MS/MS |
Selenium |
Plasma, prostate tissue |
AA |
Serotonin |
Plasma; Tissue; Urine |
HPLC-MS/MS |
SGM45 |
Mouse Plasma |
HPLC-MS/MS |
Sphingosine/Sphinogsine-1-P |
Cells; plasma; Urine; tissue |
*HPLC-MS/MS |
Sphingomyelin |
Cells; plasma; Urine; tissue |
*HPLC-MS/MS |
Sulindac/Sulindac metabolites |
Plasma; Breast Fluid; Skin |
HPLC-MS/MS |
Targretin |
Plasma |
HPLC-FLD |
Taurine |
Urine |
HPLC-MS/MS |
Tea Catechins |
Plasma; Urine |
HPLC-EC |
Testosterone |
Plasma |
HPLC-MS/MS |
TC1S2(iron chelator) |
Mouse Plasma |
HPLC-MS/MS |
TC4G6(iron chelator) |
Mouse Plasma |
HPLC-MS/MS |
Thyroxine/Triiodothyroxine |
Plasma |
HPLC-MS/MS |
Tocopherol/Tocopherol succinate |
Plasma; Tissue |
HPLC-FLD |
UA8967 |
Plasma |
HPLC-MS/MS |
Withaferin analogues |
Plasma |
HPLC-MS/MS |
Wortmannin analogues |
Plasma; Bile |
HPLC-MS/MS |
Zileuton |
Plasma |
HPLC-MS/MS |
DISCOVERY (untargeted) Metabolomics and Lipidomics –
Analysis is performed on most sample types listed above. The analysis is performed on a Thermo Vanquish Dual UPLC/Exploris 480 Orbi(producing HRAM spectra). Chromatographic strategies include Reverse Phase and HILIC (With lipid specific chromatography for Lipidomics). Sample preparation is available through the resource. Samples are processed utilizing Thermo Compound Discoverer and/or Lipid Search Software, statistical analysis utilizes R and Metaboanalyst. As this is typically a tailored analysis please inquire with ACSR for a consultation to discuss projects.
* = available through Sub-core
** = 9-HOTrE, 13-HOTrE, 13-oxo-ODE, 9-oxo-ODE, 13-HODE, 9-HODE, 12(13)-EpOME, 9(10)-EpOME, EKODE, 12,13-DiHOME, 9,10-DiHOME, 15-deoxy-Prostaglandin J2, 15-HEPE, 8-HEPE, 12-HEPE, 5-HEPE, 17(18)-EpETE, 15-oxo-ETE, 14(15)-EpETE, 11(12)-EpETE, 8(9)-EpETE, 12-oxo-ETE, 5-oxo-ETE, 20-HETE, 15-HETE, 11-HETE, 8-HETE, 12-HETE, 9-HETE, 5-HETE, 14(15)-EET, 11(12)-EET, 8(9)-EET, 5(6)-EET, 15(S)-HETrE, Prostaglandin J2, Prostaglandin B2, 8,15-DiHETE, 6-trans-Leukotriene B4, 5,15-DiHETE, 17,18-DiHET, Leukotriene B4, 14,15-DiHETE, 5,6-DiHETE, 14,15-DiHET, Leukotriene B3, 11,12-DiHET, 8,9-DiHET, 5,6-DiHET, 17-HDHA, 19(20)-EpDPA, 16(17)-EpDPA, 13(14)-EpDPA, 10(11)-EpDPA, 7(8)-EpDPA, Prostaglandin E3, Prostaglandin D3, 20-OH-Leukotriene B4, Prostaglandin E2, Prostaglandin D2, Lipoxin A4, Prostaglandin F2a, Prostaglandin E1, Prostaglandin D1, 19,20-DiHDPE, 20-COOH-LTB4, 6-keto-PGF1a, TXB2, Resolvin D1
*** = 3-hydroxyanthranilic acid, quinolinic acid, anthranilic acid, L-tryptophan, L-kynurenine, kynurenic acid, 3-hydroxykynurenine, cinnabarinic acid, xanthurenic acid, N-formylkynurenine, picolinic acid, 5-hydroxytryptophan, serotonin, melatonin, tryptamine, glutamic acid, dopamine
University of Arizona Cancer Center, Room 4965
Co-Director
Co-Director
Manager
Wade Chew
wchew@arizona.edu
Contact
Potential users, especially first-time users, are encouraged to personally contact ACSR service personnel for instructions on how to access all the services of the Analytical Chemistry Shared Resource. Please contact Dr. Chow by phone or email. After a short discussion about your project, the service request form can be submitted to the ACSR and a realistic time line can be projected.
All University of Arizona Cancer Center members have access to the Analytical Chemistry Shared Resource. The service is provided according to the following University of Arizona Cancer Center priority guidelines
- University of Arizona Cancer Center members with peer-reviewed extramural funding;
- New University of Arizona Cancer Center investigators with University of Arizona Cancer Center pilot project or developmental funding;
- University of Arizona Cancer Center members with other funding sources;
- Peer-reviewed, funded non-members at University of Arizona if sufficient time/resources are available to accommodate requested service.